Menopause and metabolic syndrome: A study of 498 urban women from western India

Shefali Pandey, Manisha Srinivas, Shubhada Agashe, Jayashree Joshi, Priti Galvankar, C. P. Prakasam, Rama Vaidya

Medical Research Centre of Kasturba Health Society, ICMR Advanced Center of Reverse Pharmacology, 17, Khandubhai Desai Road, Vile Parle, Mumbai - 400 052, India

ABSTRACT

Introduction: Metabolic syndrome (MS) is a cluster of risk factors for future development of type 2 diabetes mellitus and cardiovascular diseases. Menopausal transition with its incidental hormonal changes is considered to contribute to the development of MS. However, age is known to influence MS risk factors.

Objective: The present study explores the prevalence of MS in pre- and postmenopausal women from western India.

Methods: Four hundred and ninety eight women above 35 years of age, participating in women’s health care program were assessed for the prevalence of MS using two criteria- International Diabetes Federation criteria (IDF) and Harmonization (H_MS) criteria.

Results: Prevalence of MS amongst postmenopausal women was significantly higher ($P < 0.001$) than that in premenopausal women by both, IDF (premenopausal 45% and postmenopausal 55%) and H_MS criteria (premenopausal 44% and postmenopausal 56%). However, this significance disappeared when data was adjusted for the confounding variable of age.

Key Words: International diabetes federation criteria, Indian women, harmonization criteria, menopause, metabolic syndrome

INTRODUCTION

Metabolic syndrome (MS), a cluster of factors like dysglycemia, dyslipidemia, central obesity and hypertension, is known to pronounce risk for future development of Type 2 diabetes mellitus and cardiovascular diseases (CVD). Studies show that MS and CVD are more common in women above 55 years of age with significant increase in individual risk factors in the postmenopausal phase. Changing hormonal milieu with declining estrogen and alteration of its ratio with testosterone has been implicated as a causal factor for the emergence of MS at menopausal transition. Besides menopausal hormonal changes, ageing also contributes to clustering of cardio-metabolic risk factors at this time. Hence, there is a debate as to whether the increased incidence occurs due to ageing alone or due to menopausal transitional changes.

Prevalence of MS has varied greatly in different populations. Prevalence of MS amongst pre-and postmenopausal women has ranged from 13.8% in premenopausal to more than 60% in postmenopausal women. These differences are probably related to ethnic variations, different criteria used for its definition, study design and sample size. Asian Indians, in general, are prone to have MS at a younger age and have severe morbidity and mortality consequences as compared to Caucasians. Recent studies of MS in Indian menopausal women show a prevalence ranging from 19.2% in premenopausal to 32.4% in postmenopausal women. The criteria used to define MS have also been under considerable debate. The earlier criteria used by the National Cholesterol Education Program’s...
Adult Treatment Panel III (NCEP-ATP III) \cite{22} were modified in 2005 by including ethnic-specific waist circumference as a measure of visceral obesity to create the International Diabetes Federation (IDF) criteria. \cite{23} However, recently an expert group from the IDF, National Heart, Lung, Blood Institute (NHLBI), World Health Federation and other international associations proposed a harmonized definition (H_MS) that uses uniform cut points for all the risk factors and recommended ethnicity-specific waist circumferences in the criteria for defining MS.\cite{24,25}

The current study was carried out to determine the prevalence of MS and its components in pre- and postmenopausal women (using IDF and Harmonization criteria) and their association with menopausal status.

**MATERIALS AND METHODS**

Data were collected retrospectively from 701 women aged 35 to 66 years participating in a women’s health checkup program (MAITREYI Comprehensive healthcare program) at our center. Women who were not using hormonal therapy for the past six months were included. The participants were urban women from middle and higher middle class strata residing in the western suburbs of Mumbai and were non-smokers/alcoholics. Participants who had one or more missing values of the risk factors necessary for a diagnosis of MS were excluded. Ultimately, a total of 498 women were included for the present study in examining the prevalence of MS in establishing its relation with MS factors and age. They were divided into two groups: premenopausal and perimenopausal vs. postmenopausal women (as per following definitions: Premenopause - Period during which climacteric women still have menstrual cycles, whether such cycles are regular or not. Perimenopause or menopausal transition - Period that extends from two years before the last menstruation and until one year later. Women have irregular menstrual cycles and endocrine changes. Postmenopause - Period that starts one year after the last menstruation. It is subdivided into early (up to five years after the last menstruation) or late (more than five years after the last menstruation).

A predesigned and validated case record form was filled out at the time of registration. This form contained: age, menopausal status (pre or postmenopausal), socioeconomic class, personal and family history, smoking, alcoholism, current medicine intake. All participants underwent examinations that included interviews for any menopausal symptoms and of MS, CVD. A general, gynecological and systemic examination, including blood pressure measurement and anthropometry (height, weight, abdominal circumference (AC), hip circumference (HC) and Body mass index (BMI)) were performed. Subjects were weighed with light clothes and no footwear and height was measured in centimeters using a stadiometer (Halden). Waist circumference was measured at a level midway between the bottom of the rib cage and superior margin of iliac crests during inspiration and hip circumference at the maximal diameter of the buttocks.

Venous blood was collected in the morning after an overnight fast of 12 h. Blood was collected for complete blood count (CBC), erythrocyte sedimentation rate (ESR), blood glucose, lipids (cholesterol, triglycerides, HDL-C, and LDL-C), serum creatinine and thyroid stimulating hormone (TSH). All women underwent an oral glucose tolerance test using 75 g oral glucose for estimation of blood glucose. After the fasting blood sample was collected 75 g glucose was administered orally and blood collected after 1 and 2 h for blood glucose estimations. The laboratory had internal and external quality control throughout the study.

**Laboratory methods**

Total cell count was carried out on the automated cell counter (Sysmex K1000), whereas lipid profiling was carried out by ERBA test kits. Plasma glucose was estimated by Accurex test kit, serum creatinine was done using Ark diagnostics test kits. All biochemical estimations were done using ERBA CHEM PRO instrument. Hormonal tests were done using radio immune assay (DSL kits).

**Statistical analysis**

The data were presented as mean, standard deviation, percentages, odds ratios and confidence intervals. Chi-square test was used to establish association between MS and age group, and MS factors.

The baseline characteristics of premenopausal and postmenopausal women were compared using an ANCOVA with age as the covariate. Out of 498 women, 112 who were on antihypertensive medications were excluded from comparison of mean blood pressure and 43 known diabetics were excluded from comparison of mean fasting glucose level while profiling the two groups.

The relationship between the menopausal status and
MS was observed in a simple logistic regression model, with the odds ratio and its confidence interval being estimated at 95%. Bivariate analysis of age group, menopausal status and MS factors has been carried out. Multivariate logistic regression analysis was used to assess the independent contribution of menopausal status to the presence of MS with an adjustment for age (a continuous variable). The analysis was carried out separately for MS with IDF (International Diabetic Forum) definition and MS with Harmonization Definition (H_MS) and the components considered for IDF and H_MS are given in Table 1. A P value < 0.05 was considered statistically significant.

RESULTS

The average age of the study women was 49.8 ± 8.49 years. Out of 498 study women, 274 (55.0%) were premenopausal and 224 (45.0%) were postmenopausal. Baseline characteristics of pre- and postmenopausal women are shown in Table 2.

Postmenopausal women had significantly higher (P < 0.0001) mean systolic blood pressure, pulse pressure, total cholesterol, triglycerides and LDL cholesterol and fasting blood sugar (P < 0.01) than premenopausal women adjusted for age [Table 2].

The Prevalence of MS by IDF criteria was 56.6% (282/498 cases) while by H_MS it was 58.4% (291/498 cases). MS was more prevalent among postmenopausal women than among premenopausal women. According to IDF criteria 55.0% of postmenopausal women had MS compared to 45.0% of premenopausal women with OR = 1.166 (CI = 0.665 to 2.045), P < .0001. Similarly, it has been observed that the prevalence of MS according to H_MS criteria was 44% in premenopausal as compared to 56% in postmenopausal women with OR = 1.248 (CI = 0.707 – 2.205) [Table 3].

A statistically significant relationship between increasing age and occurrence of MS (P < .0001) was observed. Older women (≥56) were 4.096 (CI: 1.704-9.848) times at risk being diagnosed with MS as compared to younger women less than or equal to 40 years using the IDF criteria and 3.672 (CI: 1.515-8.901) using the H_MS criteria [Table 4].

Results of the multivariate analysis of MS adjusted for age and menopausal status using the IDF and H_MS criteria are given in Table 5. There was a statistically significant relationship between increase in age and prevalence of MS, by both criteria (P < .0001). A 4.7 times increase in the risk of MS among women aged

---

### Table 1: Components of metabolic syndrome in study women

| Risk Factors for metabolic syndrome | Value | Additional criteria |
|-----------------------------------|-------|---------------------|
| Waist circumference (Central obesity) | ≥ 80cm |                  |
| Triglycerides | ≥150 mg/dl | Or on treatment for Dyslipidemia |
| HDL-C | <50 mg/dl | Or under treatment for Dyslipidemia |
| Blood Pressure: Systolic BP | >130 mm Hg | Or treatment of previously diagnosed hypertension |
| diastolic BP | >85 mm Hg |                  |
| Fasting blood glucose | ≥100 mg/dl | Or previously diagnosed diabetic on treatment |

For IDF criteria: Central obesity with any other two factors
For Harmonization: Any three of the above six factors

### Table 2: Baseline characteristics of pre- and postmenopausal women participating in the study

| Variables | Premenopause (274) | Postmenopause (224) | Total (498) | AVCOVA (P value) |
|-----------|---------------------|---------------------|-------------|------------------|
| Age (years) | Mean | Std. Deviation | Mean | Std. Deviation | Mean | Std. Deviation | 49.28 | 8.49 | <.0001 |
| BMI (Kg/m^2) | 27.23 | 4.51 | 27.70 | 4.70 | 27.45 | 4.60 | <.611 |
| WC | 87.11 | 10.70 | 89.43 | 10.91 | 88.16 | 10.84 | <.0001 |
| SYBP* | 122.58 | 14.11 | 131.12 | 18.62 | 125.94 | 16.55 | <.024 |
| DYBP* | 79.03 | 7.92 | 80.83 | 7.97 | 79.74 | 7.98 | <.0001 |
| Pulse pressure* | 43.55 | 10.20 | 50.29 | 13.91 | 46.20 | 12.24 | <.024 |
| FBS† | 82.54 | 15.73 | 89.44 | 25.70 | 85.51 | 20.70 | <.0001 |
| CHO | 195.41 | 36.06 | 213.50 | 37.59 | 203.55 | 37.81 | <.0001 |
| HDL | 48.74 | 11.17 | 49.31 | 11.12 | 49.99 | 11.14 | <.566 |
| TG | 114.01 | 55.25 | 146.55 | 86.06 | 128.64 | 72.54 | <.0001 |
| LDL | 122.70 | 33.93 | 134.39 | 34.81 | 127.95 | 34.78 | <.0001 |

Data are mean ± SD. ANCOVA with age as a covariate. * Of 498 women, 112 on hypertension medications were excluded from comparison of mean blood pressure. † Of 498 women, 43 on diabetic medications were excluded from comparison of mean blood sugar fasting.
56-65 (OR: 4.747, CI: 1.914-11.774) compared to those less than 40 years was observed with the IDF criteria and OR 4.045 was observed using the H_MS criteria.

The multivariate analysis of MS (IDF and H_MS criteria) could not show a significant relationship between age-adjusted MS and menopausal status [Table 5] but the risk of MS was found to be more among postmenopausal as compared with premenopausal women.

The prevalence of MS has greatly varied across different studies [Table 6].

National Cholesterol Education Program’s Adult Treatment Panel III - NCEP-ATP III, the International Diabetes Federation – IDF, World Health Organization – WHO, Harmonization – H_MS, NA: Not applicable

**DISCUSSION**

The prevalence of MS by IDF criteria was 56.6% (282/498 cases) while by the H_MS it was 58.4% (291/498 cases). Use of harmonization criteria resulted in a higher prevalence than with the IDF criteria, though not statistically significant. The prevalence of MS was higher among postmenopausal as compared to premenopausal women in the current study using both IDF and H_MS criteria. In the present study 55 and 56% postmenopausal and 45 and 44% premenopausal women according to IDF and H_MS criteria respectively were found to have MS. Prevalence of MS was found to be more among older women (56+) as compared to the younger cohort. This finding was statistically significant in both the univariate analysis and multivariate analysis. The higher prevalence of MS in postmenopausal women was not statistically significant after adjustment for age as a confounding variable in the current study.

### Table 3: Prevalence of metabolic syndrome according to IDF and HN criteria by menopausal status

| n   | Menopausal status | IDF criteria | Harmonization criteria (H_MS) |
|-----|------------------|--------------|-----------------------------|
|     |                  | %MS          | OR† CI 95%†                  | %MS          | OR† CI 95%†                  |
|     |                  |              | P Value                      |              | P Value                      |
|     | Premenopause (ref) | 274          | 127 (45.0) 1.000             | 128 (44.0) 1.000                      |
|     | Postmenopause    | 224          | 155 (55.0) 1.166 0.665-2.045 | 163 (56.0) 1.248 0.707-2.205           |
| Total | 498              | 282          |                             | 291          |

*Chi-square test, † derived from Logit Regression, ref: reference category

### Table 4: Prevalence of metabolic syndrome according to IDF and HN criteria by age

| n   | Age group (years) | IDF criteria | Harmonization criteria (H_MS) |
|-----|------------------|--------------|-----------------------------|
|     |                  | %MS          | OR† CI 95%†                  | %MS          | OR† CI 95%†                  |
|     |                  |              | P Value                      |              | P Value                      |
|     | ≤40 (ref)        | 66           | 23 (34.8) 1.000              | 27 (40.9) 1.000                      |
|     | 41-45            | 124          | 47 (37.9) 1.127 0.603-2.105  | 44 (35.5) 0.780 0.422-1.443            |
|     | 46-50            | 126          | 83 (65.9) 3.394 1.747-6.592  | 83 (65.1) 2.465 1.285-4.728            |
|     | 51-55            | 86           | 60 (69.8) 3.830 1.705-8.602  | 60 (69.8) 3.769 1.663-8.545            |
|     | ≥ 56             | 96           | 69 (71.9) 4.096 1.704-9.848  | 69 (71.9) 3.672 1.515-8.901            |

*Chi-square test, † derived from Logit Regression, ref: reference category

### Table 5: Multivariate analysis of MS (IDF, Harmonization criteria) adjusted for age, menopausal status among study women

| Age group and menopausal status | IDF criteria | Harmonization criteria (H_MS) |
|-------------------------------|--------------|-----------------------------|
| Age group (years)             | OR CI 95%    | P Value                     | OR CI 95%    |
| ≤40 (ref)                     | 1 0.670-2.546| .0001                       | 1 0.449-1.645|
| 41-45                         | 1.306 1.944-7.956|                | 0.859 1.370-5.380 |
| 46-50                         | 3.933 1.911-10.310|               | 2.715 1.784-9.662 |
| 51-55                         | 4.439 1.914-11.774|               | 4.151 1.629-10.045 |
| ≥ 56                          | 4.747        |                            | 4.045        |
| Menopausal status             |              |                             |              |
| Premenopause (ref)            | 1 0.655-2.045| 0.591 0.445                 | 1 0.707-2.205|
| Postmenopause                 | 1.166        |                            | 1.248        |
The prevalence of MS has greatly varied across different studies as shown in Table 6 (vide supra). Differences in socio-environmental and genetic factors, lifestyles, type of menopause (natural/surgical), time since menopause and criteria used for defining MS could be some of the reasons for this variability. The prevalence of MS in premenopausal women varied from 13.8% in a study from Korea to 46.4% in the present study. In another study from India, a prevalence of 22.2% in the premenopausal as compared to 32.42% in the postmenopausal group was reported. In the Santiniketan women study, 214 women were studied for clustering of cardio-metabolic risk factors which were found to be higher in the postmenopause phase. Though all studies for the prevalence of MS in menopausal women have shown a higher percentage of MS in postmenopausal as compared to premenopausal women, most have been cross-sectional. Heidari et al., in a study of 1596 women showed a prevalence of 44.9%, 57.9% and 64.3% in pre-, peri- and postmenopausal women respectively. Janssen et al., in the Study of Women’s Health Across the Nation (SWAN), followed 949 premenopausal women over nine years. By the final menstrual cycle, a 13.7% incidence of new-onset MS was observed with an odds ratio of 1.45 (95% CI 1.35–1.56) of developing MS/year in the perimenopausal years. The authors attributed this to progressive androgenization rather than decline in estrogen levels during the climacteric transition.

In the current study, the prevalence of MS was found to be more among older women (≥51 years, OR 4.439, CI 95% 1.914-11.774) as compared to the younger cohort. This finding was statistically significant in both the univariate analysis and multivariate analysis. Women in the higher age group had a statistically significant higher prevalence of MS when adjusted for age and menopausal status with both criteria (IDF and HN). Though there was a higher prevalence of MS among postmenopausal women when both criteria were considered, this difference was not statistically significant after the adjustment for age. There is current controversy on whether MS worsens with age alone or as a result of the menopausal transition. The Framingham cohort demonstrated fourfold increase in the incidence of CVD in the postmenopausal phase. Women with either surgical or early menopause have also been shown to have a higher CVD risk. However, all studies do not show causal effects of menopause and attribute the increased prevalence of MS in postmenopausal period to ageing. In a cross-sectional study from Brazil, though the prevalence of MS was higher in the post-menopause women, the effect was not statistically significant and ageing was the chief factor for the increase.

### Table 6: Prevalence of MS in various studies

| Author, year | Country, number of subjects (n) | Criteria for MS | Prevalence of MS according to menopausal status (%) |
|--------------|---------------------------------|-----------------|-----------------------------------------------------|
| Hidalgo LA, 2006 | Ecuador, 325 | NCEP III (ATP III) | Premenopausal Perimenopausal Postmenopausal |
| Piche ME, 2006 | Canada, 108 | WHO | NA NA 29.6 |
| Kim HM, 2007 | Korea, 2671 | NCEP III (ATP III) | 13.8 NA 54.6 |
| Ainy E, 2007 | Tehran, 2183 | NCEP III (ATP III) | 53 54 69 |
| Deibert P, 2007 | Germany, 76 | NCEP III (ATP III) | 23 42 |
| Janssen I, 2008 | U.S., 949 | NCEP III (ATP III) | NA NA 13.7 |
| Eshtiaghi R, 2009 | Iran, 940 | NCEP III (ATP III) | 18.3 NA 53.5 |
| Figueiredo Neto JA, 2010 | Brazil, 323 | NCEP III | 24 37 |
| Indhavivadhana S, 2010 | Thailand, 971 | NCEP III (ATP III) | NA 12.4 16.9 |
| Heidari R, 2010 | Iran, 1596 | NCEP III (ATP III) | 44.9 57.9 64.3 (surgical menopause) |
| Ruan X, 2010 | China, 181 | NCEP III (ATP III) | NA NA 33.7 |
| Tandon VR, 2010 | India, 500 | NCEP III (ATP III) | NA NA 13 |
| Current study | India, 498 | IDF, H_MS | 45 NA 55 |
| | | | 44 NA 56 |
important to recognize that premature cardiovascular morbidity and mortality are higher in Asian Indians in general.[29] The first myocardial infarction (MI) attack occurs in 4.4% of Asian women and 9.7% of men at age less than 40 years, which is 2- to 3.5-fold higher than in the West European population.[30] In the present study, though OR for MS increased with advancing age, younger women between 40–45 years also had a 35-40% prevalence of MS [Table 4]. Hence against the background of high CVD risk factors in Indian women, it would be important to follow up women of this age group as they transit into menopause to actually determine the influence of changing hormonal milieu on MS.

In conclusion the present study shows a high prevalence of MS amongst women above 35 years of age. Though the prevalence was more amongst postmenopausal women, the significance disappeared when adjusted for age. The cross-sectional nature of our study may be a limitation to show the effect of menopause on the prevalence of MS. Selection bias due to urban women from higher socioeconomic class participating in the healthcare program and the exclusion of ineligible women may be other limitations to generalize the findings to Indian women.

ACKNOWLEDGMENTS

We thankfully acknowledge Dr. Ashok Vaidya, Research Director and Dr. Deepak Dave, Medical Director of MRC of Kasturba Health Society for active guidance throughout the present study. We are grateful to MAITREYI team members-Ms. Anupama Bhaskaran, Ms. Neeru Mehta, Ms. Veena Singh, Dr. Suchitra Pandit, Dr. Nivedita Moulick and the late Dr. Pratibha Mehta. We also acknowledge Dr. Jaya Gogate and the late Dr. Meena Shringi for their contribution to the MAITREYI healthcare program.

REFERENCES

1. Sattar N, Gaw A, Scherbakova O, Ford I, O’Reilly DS, Haffner SM, et al. Metabolic syndrome with and without C-Reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108:414-9.
2. Mesch VR, Boero LE, Siseles NO, Royer M, Prada M, Sayegh F, et al. Metabolic syndrome throughout the menopausal transition: Influence of age and menopausal status. Climacteric 2006;9:40-8.
3. Lejková M, Alušík S, Suchánek M, Zecová S, Piha J. Menopause: Clustering of metabolic syndrome components and population changes in insulin resistance. Climacteric 2011;13:83-91.
4. Mesch VR, Siseles NO, Maidana PN, Boero LE, Sayegh F, Prada M, et al. Androgens in relationship to cardiovascular risk factors in the menopausal transition. Climacteric 2008;11:509-17.
5. Janssen I, Powell LH, Crawford S, Lasley B, Sutton-Tyrrell K. Menopause and the metabolic syndrome: The Study of Women’s Health Across the Nation. Arch Intern Med 2008;168:1568-75.
6. Casiglia E, d’Este D, Ginocchio G, Colangelo G, Onesto C, Tramontin P, et al. Lack of influence of menopause on blood pressure and cardiovascular risk profile: A 16-year longitudinal study concerning a cohort of 568 women. J Hypertens 1996;14:729-36.
7. Hidalgo LA, Cheddrau PA, Morocho A, Alvarado M, Chavez D, Huc A. The metabolic syndrome among postmenopausal women in Ecuador. Gynecol Endocrinol 2006;22:447-54.
8. Piché ME, Weisnagel SJ, Corneau L, Nadeau A, Bergeron J, Lemieux S. The WHO and NCEP/ATPIII Definitions of the Metabolic Syndrome in Postmenopausal Women: Are They So Different? Metab Syndr Relat Disord 2006;4:17-27.
9. Kim HM, Park J, Ryu SY, Kim J. The effect of menopause on the metabolic syndrome among Korean women: The Korean National Health and Nutrition Examination Survey, 2001. Diabetes Care 2007;30:701-6.
10. Ainy E, Mirimiran F, Zahedi Aasl S, Azizi F. Prevalence of metabolic syndrome during menopausal transition Tehranian women: Tehran Lipid and Glucose Study (TLGS). Maturitas 2007;58:150-5.
11. Deibert P, König D, Vitalins MZ, Landmann U, Frey I, Zahradnik HP, et al. Effect of a weight loss intervention on anthropometric measures and metabolic risk factors in pre-versus postmenopausal women. Nutr J 2007;6:31.
12. Eshtiaghi R, Esteghamati A, Nakhjavani M. Menopause is an independent predictor of metabolic syndrome in Iranian women. Maturitas 2010;65:262-6.
13. Figueiredo Neto JA, Figueirêdo ED, Barbosa JB, Barbosa Fde F, Costa GR, Nina VJ, et al. Metabolic syndrome and menopause: Cross-sectional study in gynecology clinic. Arq Bras Cardiol 2010;95:339-45.
14. Indhavivadhana S, Rattanachaïyanont M, Wongvanaranurak T, Kanboon M, Techatraïsak K, Leerasiri P, et al. Predictors for metabolic syndrome in perimenopausal and postmenopausal Thai women. Climacteric 2010 [In Press].
15. Heidari R, Sadeghi M, Talaei M, Rabiei K, Mohammadiard N, Sarrazafadegan N. Metabolic syndrome in menopausal transition: Isfahan Healthy Heart Program, a population based study. Diabetol Metab Syndr 2010;2:59.
16. Ruan X, Jin J, Hua L, Liu Y, Wang J, Liu S. The prevalence of metabolic syndrome in Chinese postmenopausal women and the optimum body composition indices to predict it. Menopause 2010;17:566-70.
17. Tandon VR, Mahajan A, Sharma S, Sharma A. Prevalence of cardiovascular risk factors in postmenopausal women: A rural study. J Mid life Health 2010;1:26-9.
18. Misra A, Khurana L. The metabolic syndrome in South Asians: Epidemiology, determinants, and prevention. Metab Syndr Relat Disord 2009;7:497-514.
19. Pan WH, Yeh WT, Weng LC. Epidemiology of metabolic syndrome in Asia. Pac J Clin Nutr 2008;17:37-42.
20. Balasubramanyam A, Rao S, Misra RJ. Prevalence of metabolic syndrome and associated risk factors in Asian Indians. J Immigr Minor Health 2008;10:313-23.
21. Shah D. The Annual Conference of the British Menopause Society. J Mid Life Health 2010;1:48-50.
22. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
23. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new worldwide definition. A Consensus Statement from the new International Diabetes Federation. Diabet Med 2006;23:469-80.
24. Vaidya RA, Pandey SN, Srinivas M, Nabar N. Metabolic
syndrome: History synonyms and definition(s) Ed. Parihar M, Published by IMS Education Committee, Mumbai IMS Digest 2011;1:2-5.

25. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al.: Harmonizing the metabolic syndrome: A joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120:1640-5.

26. Bhagat M, Mukherjee S, De P, Goswami R, Pal S, Das M, et al. Clustering of cardiometabolic risk factors in Asian Indian women: Santiniketan women study. Menopause 2010;17:359-64.

27. Gohlke-Barwolf C. Coronary artery disease: Is menopause a risk factor? Basic Res Cardiol 2000;95:177-83.

28. Dørum A, Tonstad S, Liavaag AH, Michelsen B, Dahl AA. Bilateral oophorectomy before 50 years of age is significantly associated with the metabolic syndrome and Framingham risk score: A controlled, population-based study (HUNT-2). Gynecol Oncol 2008;109:377-83.

29. Ganguly NK, Sharma M. Premature Coronary Artery Disease in Indians and its Associated Risk Factors. Vasc Health Risk Manag 2005;1:217-25.

30. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): Case-control study. Lancet 2004;364:937-52.

Source of Support: Nil, Conflict of Interest: None declared.

Author Help: Online submission of the manuscripts

Articles can be submitted online from http://www.journalonweb.com. For online submission, the articles should be prepared in two files (first page file and article file). Images should be submitted separately.

1) First Page File:
   Prepare the title page, covering letter, acknowledgement etc. using a word processor program. All information related to your identity should be included here. Use text/rtf/doc/pdf files. Do not zip the files.

2) Article File:
   The main text of the article, beginning with the Abstract to References (including tables) should be in this file. Do not include any information (such as acknowledgement, your names in page headers etc.) in this file. Use text/rtf/doc/pdf files. Do not zip the files. Limit the file size to 1 MB. Do not incorporate images in the file. If file size is large, graphs can be submitted separately as images, without their being incorporated in the article file. This will reduce the size of the file.

3) Images:
   Submit good quality color images. Each image should be less than 4 MB in size. The size of the image can be reduced by decreasing the actual height and width of the images (keep up to about 6 inches and up to about 1800 x 1200 pixels). JPEG is the most suitable file format. The image quality should be good enough to judge the scientific value of the image. For the purpose of printing, always retain a good quality, high resolution image. This high resolution image should be sent to the editorial office at the time of sending a revised article.

4) Legends:
   Legends for the figures/images should be included at the end of the article file.
